Jean-Loup Romet-Lemonne, M.D., Non-Executive Chairman
Jean-Loup is a Senior Advisor Global Development at Institut Pasteur, promoting from New York the Institut Pasteur Global Health Genomics Initiative. He is the Founder and former CEO of IDM Pharma Inc. (formerly NASDAQ: IDMI, now part of Takeda Oncology) a developer of anti-cancer immunotherapy drugs and vaccines and a pioneer of Cancer Cellular immunotherapy. Jean-Loup got his academic training as senior scientist at the Cancer Biology Department at Harvard School of Public Health, Boston, and is a former associate professor in cellular biology at the Medical School of Tours University, France.
Helmuth van Es, Ph.D., Non-Executive member
Helmuth co-founded Galapagos, a global drug discovery company, in 1998. As Head of Science, part of the business development team of Galapagos, he negotiated and established multimillion dollar alliances with GSK, Bayer, Incyte, Pharmacia, Boehringer-Ingelheim, CF foundation and others. Since Galapagos Helmuth founded BioConsilium and co-founded drug-discovery companies Audion Therapeutics (2008 based on Harvard IP) targeting hearing loss, Eli Lilly and INKEF are current investors; Effecta Pharma focussing on novel antivirals (2009) (Dengue, Rhinovirus etc); Citryll a single asset company focussing on a first in class NET inhibiting therapeutic antibody targeting RA and other autoimmune diseases.
Geoff Lawton, Ph.D., Non-Executive member
Geoff has extensive experience in new medicine discovery across many therapeutic areas and is a co-inventor of a marketed drug (Cilazapril). He is a former Director of Chemistry at Roche UK, and Vice-president Chemistry and Preclinical Sciences within Roche Bioscience, Palo Alto, USA. He was the founding Research Director with Lectus Therapeutics building from start-up a drug discovery organisation; generating the team, facilities and project portfolio targeting the next generation of ion channel modulating medicines. Geoff provides scientific and strategic evaluation and advice as an independent consultant to a wide range of drug discovery organisations. Clients include large and small biopharma companies, CROs, VCs, academic groups and medical research charities. He is a founder of INMedD, a new medicines discovery social enterprise.
Gordon Waldron, Non-Executive member
Gordon has over 25 years’ experience in high tech, med tech and biotech. During his career, he has raised over €M140 in venture capital funding, over €M50 in an IPO and has been involved in 9 M&A transactions. Gordon is the Former Vice President and Chief Financial Officer of the antibacterial drug discovery company Novexel. At Novexel, he participated in a preclinical license negotiation which brought the company a €75 million upfront payment in 2008 and he negotiated the sale of Novexel to AstraZeneca for cash consideration of approximately €500 million in 2009.
Marc Lemonnier, Executive member, Chief Executive Officer
Marc is the CEO and co-founder of Antabio and a member of the Board of the European Alliance of Biopharmaceutical companies combating Anti-Microbial resistance (BEAM Alliance). A molecular microbiologist by training, Marc is the author of numerous peer-reviewed articles in the field of pathogenic bacterial infections and their biology. Prior to founding Antabio, Marc held different research positions at various institutions globally such as CNRS and Inserm (France), CSIC (Spain) and Emory University (USA). At Antabio, Marc structured the corporate and financial aspects of the company and successfully managed Antabio’s fundraisings using different strategies including innovative tools such as crowdfunding (Antabio being the world-premier crowdfunding exit for a biotech start-up). Under Marc’s leadership, ANTABIO has attracted low double-digit million funding and received numerous awards including the BIOVISION Investment Conference Award (2016), the “Concours Mondial de l’Innovation” Worldwide Innovation Challenge (2014), and two Seeding Drug Discovery Awards from the Wellcome Trust (2013 and 2015).